Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Cisplatin in Non-pCR TNBC
NCT04297267Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Feb 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoint: Disease free survival at 3 years. Status: unknown.
02
Drugs
gemcitabinecisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04297267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297267.